<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>An Adaptive Machine Learning Triage Framework for Predicting Alzheimer's Disease Progression - Health AI Hub</title>
    <meta name="description" content="This paper introduces a two-stage machine learning framework to address the cost-accuracy dilemma in predicting Alzheimer's Disease (AD) progression from Mild C">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>An Adaptive Machine Learning Triage Framework for Predicting Alzheimer's Disease Progression</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.06681v1" target="_blank">2511.06681v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-10
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Richard Hou, Shengpu Tang, Wei Jin
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.98 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.06681v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.06681v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a two-stage machine learning framework to address the cost-accuracy dilemma in predicting Alzheimer's Disease (AD) progression from Mild Cognitive Impairment (MCI). By selectively acquiring expensive advanced features like PET scans and CSF biomarkers based on their predicted "value of information," the framework reduces the need for such testing by 20%. It achieves a high predictive accuracy (AUROC 0.929) that is comparable to models using all advanced features, making early, reliable AD prediction more accessible and cost-effective.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This framework is highly relevant for medicine as it provides a practical solution to make accurate, early prediction of Alzheimer's disease progression more accessible and affordable. By optimizing diagnostic pathways, it enables earlier personalized therapeutic interventions, potentially slowing disease progression and improving patient outcomes, especially in resource-constrained environments.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper introduces an adaptive machine learning triage framework that predicts the conversion from mild cognitive impairment to Alzheimer's disease. Its core application is to optimize the diagnostic process by selectively recommending advanced, costly medical tests based on their predicted 'value of information', thereby reducing the overall cost and making early, reliable AD prediction more accessible and efficient in real-world clinical practice.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the challenge of balancing high predictive accuracy (from costly advanced tests like PET/CSF) with the prohibitive expense of obtaining these tests for all MCI patients.</li>
                    
                    <li>Proposes a two-stage machine learning triage framework that adaptively decides when to acquire advanced, costly features.</li>
                    
                    <li>The decision to obtain advanced features is based on their predicted "value of information," optimizing for cost-effectiveness.</li>
                    
                    <li>Utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) for predicting AD progression in MCI patients.</li>
                    
                    <li>Successfully reduced the necessity for advanced diagnostic testing by 20% compared to a strategy where all advanced tests are performed.</li>
                    
                    <li>Achieved a high test AUROC of 0.929, which was statistically comparable (p=0.1010) to a model that indiscriminately used all basic and advanced features (AUROC 0.915).</li>
                    
                    <li>Includes an interpretability analysis to explain the triage decisions, enhancing trust and clinical applicability.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study employs a two-stage machine learning framework. The initial stage uses readily available, less expensive basic clinical and cognitive features to make an initial risk assessment. For patients where the initial assessment is uncertain or the potential gain in predictive power is high, the framework selectively triggers the acquisition of advanced, costly features (e.g., PET scans, CSF biomarker analysis) based on their predicted "value of information." A subsequent machine learning model then incorporates these advanced features for refined prediction. An interpretability component is integrated to explain the rationale behind the triage decisions.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The adaptive machine learning framework reduced the need for expensive advanced diagnostic testing by 20%. Despite this reduction, it maintained a high predictive accuracy, achieving a test AUROC of 0.929. This performance was statistically comparable (p=0.1010) to a model that used both basic and all advanced features (AUROC 0.915). The framework also offers an interpretable mechanism for its triage decisions.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This framework offers a significant clinical impact by optimizing diagnostic pathways for Alzheimer's Disease. It can substantially reduce healthcare costs associated with advanced testing while maintaining high predictive accuracy, thereby making early and reliable AD prediction more accessible. This enables clinicians to provide timely, personalized therapy for MCI patients at higher risk of conversion, potentially improving patient management and outcomes in real-world practice by balancing diagnostic efficiency with economic feasibility.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The current study is noted to have considered only a limited scope of advanced features. Additionally, the findings require larger-scale validation to ensure generalizability across diverse populations and clinical settings.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Future research should focus on incorporating multiple categories of advanced features into the framework to enhance its comprehensiveness. Furthermore, larger-scale validation studies are recommended to confirm the framework's robustness and generalizability in broader clinical contexts.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Neurology</span>
                    
                    <span class="tag">Geriatrics</span>
                    
                    <span class="tag">Dementia Care</span>
                    
                    <span class="tag">Diagnostic Imaging</span>
                    
                    <span class="tag">Clinical Informatics</span>
                    
                    <span class="tag">Health Economics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Alzheimer's Disease</span>
                    
                    <span class="tag tag-keyword">Mild Cognitive Impairment</span>
                    
                    <span class="tag tag-keyword">Machine Learning</span>
                    
                    <span class="tag tag-keyword">Predictive Modeling</span>
                    
                    <span class="tag tag-keyword">Cost-Effectiveness</span>
                    
                    <span class="tag tag-keyword">Triage</span>
                    
                    <span class="tag tag-keyword">Biomarkers</span>
                    
                    <span class="tag tag-keyword">ADNI</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Accurate predictions of conversion from mild cognitive impairment (MCI) to
Alzheimer's disease (AD) can enable effective personalized therapy. While
cognitive tests and clinical data are routinely collected, they lack the
predictive power of PET scans and CSF biomarker analysis, which are
prohibitively expensive to obtain for every patient. To address this
cost-accuracy dilemma, we design a two-stage machine learning framework that
selectively obtains advanced, costly features based on their predicted "value
of information". We apply our framework to predict AD progression for MCI
patients using data from the Alzheimer's Disease Neuroimaging Initiative
(ADNI). Our framework reduces the need for advanced testing by 20% while
achieving a test AUROC of 0.929, comparable to the model that uses both basic
and advanced features (AUROC=0.915, p=0.1010). We also provide an example
interpretability analysis showing how one may explain the triage decision. Our
work presents an interpretable, data-driven framework that optimizes AD
diagnostic pathways and balances accuracy with cost, representing a step
towards making early, reliable AD prediction more accessible in real-world
practice. Future work should consider multiple categories of advanced features
and larger-scale validation.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>Findings paper presented at Machine Learning for Health (ML4H)
  symposium 2025, December 1-2, 2025, San Diego, CA, USA, 9 pages. Shengpu Tang
  and Wei Jin contributed equally as senior authors</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>